Dipentum Side Effects
Generic Name: olsalazine
Note: This page contains information about the side effects of olsalazine. Some of the dosage forms included on this document may not apply to the brand name Dipentum.
For the Consumer
Applies to olsalazine: oral capsule
In addition to its needed effects, some unwanted effects may be caused by olsalazine (the active ingredient contained in Dipentum). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking olsalazine, check with your doctor or nurse as soon as possible:Rare
- Back or stomach pain (severe)
- bloody diarrhea
- fast heartbeat
- nausea or vomiting
- skin rash
- swelling of the stomach
- yellow eyes or skin
Some of the side effects that can occur with olsalazine may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Abdominal or stomach pain or upset
- loss of appetite
- Aching joints and muscles
- anxiety or depression
- dizziness or drowsiness
- trouble in sleeping
For Healthcare Professionals
Applies to olsalazine: oral capsule
During clinical trials, olsalazine (the active ingredient contained in Dipentum) was discontinued due to side effects in 10.4% of patients compared to 6.7% of patients receiving placebo. The side effects leading to treatment withdrawal included diarrhea/loose stools (5.9%), abdominal pain (1.1%), and rash/itching (1.1%). Side effects leading to olsalazine withdrawal in less than 1% of patients included nausea, headache, heartburn, rectal bleeding, insomnia, dizziness, anorexia, lightheadedness, and depression.
Diarrhea may be minimized by initiating therapy with lower doses and gradually increasing therapy as tolerated. Administration of smaller doses more frequently may also minimize diarrhea. Diarrhea induced by olsalazine (the active ingredient contained in Dipentum) differs from diarrhea due to colitis because of the absence of blood.[Ref]
Gastrointestinal side effects have included diarrhea (11.1% to 17%), abdominal pain/cramps (10.1%), nausea (5%), dyspepsia (4.0%), bloating (1.5%), vomiting (1%), and stomatitis (1.0%). Heartburn, upper abdominal pain, diarrhea with dehydration, dry mouth, epigastric discomfort, flare in symptoms, flatulence, pancreatitis, increased blood in stool, rectal bleeding, and rectal discomfort have been reported.[Ref]
Nervous system side effects have included headache (5%), vertigo/dizziness (1%), lightheadedness, insomnia, tinnitus, paresthesia, and tremors. Paresthesia and peripheral neuropathy have been reported during postmarketing experience of products containing or metabolized to mesalamine.[Ref]
A patient who developed thyroid disease 9 days after starting olsalazine (the active ingredient contained in Dipentum) was given propranolol and radioactive iodine and subsequently developed shortness of breath and nausea. Five days later, the patient died with signs and symptoms of acute diffuse myocarditis.
Cardiovascular side effects have included chest pains, second degree heart block, myocarditis, palpitations, pericarditis, peripheral edema, shortness of breath, tachycardia, hypertension, and orthostatic hypotension.
Musculoskeletal side effects have included arthralgia/joint pain (4%), muscle cramps, muscle stiffness, and weakness. Myalgia has been reported during postmarketing experience of products containing or metabolized to mesalamine.[Ref]
Dermatologic side effects have included rash (2.3%), itching (1.3%), alopecia, erythema, and photosensitivity reaction. Angioneurotic edema has been reported during postmarketing experience of products containing or metabolized to mesalamine.[Ref]
Other side effects have included fatigue/drowsiness/lethargy (1.8%), fever chills, hot flashes, irritability, and rigors. Pyrexia has been reported during postmarketing experience of products containing or metabolized to mesalamine.
Respiratory side effects have included upper respiratory infection (1.5%). Dyspnea and interstitial lung disease have been reported during postmarketing experience of products containing or metabolized to mesalamine.
Hepatic side effects have included granulomatous hepatitis (rare), nonspecific reactive hepatitis (rare), elevated ALT (SGPT) and AST (SGOT), and at least one case of cholestatic hepatitis. Increased hepatic enzymes, increased bilirubin, hepatitis, reports of hepatotoxicity, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, and possible hepatocellular damage including liver necrosis and liver failure have been reported during postmarketing experience of products containing or metabolized to mesalamine. Some of these cases were fatal. At least one case of Kawasaki-like syndrome, which included hepatic function changes, was also reported during postmarketing experience of products containing or metabolized to mesalamine.[Ref]
Cholestatic hepatitis has been reported in one patient. Olsalazine was confirmed as the causative agent by rechallenge. Liver function abnormalities returned to normal within 2 to 8 weeks after discontinuation of the drug.[Ref]
Hematologic side effects have included anemia, hemolysis, thrombocytopenia, eosinophilia, hemolytic anemia, interstitial pulmonary disease, leukopenia, lymphopenia, neutropenia, and reticulocytosis. Aplastic anemia and pancytopenia have been reported during postmarketing experience of products containing or metabolized to mesalamine.[Ref]
Renal side effects have included nephrotic syndrome. Renal toxicity, elevated BUN, and elevated creatinine have been reported with mesalamine.[Ref]
Renal toxicity findings due to mesalamine have been similar to NSAID-induced renal disease, and included proteinuria, elevated BUN and creatinine, oliguria, polyuria, polydipsia, and rarely ocular symptoms.[Ref]
Immunologic side effects have included bronchospasm and erythema nodosum.
Genitourinary side effects have included dysuria, hematuria, interstitial nephritis, proteinuria, urinary frequency, impotence, and menorrhagia. Oliguria and polyuria have been reported with mesalamine. Interstitial nephritis has been reported during postmarketing experience of products containing or metabolized to mesalamine.
Renal toxicity findings due to mesalamine have been similar to NSAID-induced renal disease, and included proteinuria, elevated BUN and creatinine, oliguria, polyuria, polydipsia, and rarely ocular symptoms.
A 71-year-old man who had received olsalazine 250 mg orally two times a day for 8 months for treatment of colitis developed fever and transient blindness in the left eye. Percutaneous renal biopsy revealed severe interstitial nephritis. After discontinuation of the olsalazine, the fever and blindness resolved.
Psychiatric side effects have included depression (1.5%) and mood swings.
Metabolic side effects have included anorexia (1.3%). Polydipsia has been reported with mesalamine.
Ocular side effects have included dry eyes, blurred vision, watery eyes, and transient blindness. Ocular symptoms have been reported with mesalamine.[Ref]
A case of blurred vision resolved with olsalazine discontinuation and recurred on rechallenge.[Ref]
Hypersensitivity side effects have included cross-reactivity to sulfasalazine.[Ref]
Many patients who are allergic to or intolerant of sulfasalazine are able to tolerate olsalazine, although some cross-reactivity has been reported.[Ref]
1. Kiilerich S, Ladefoged K, Rannem T, Ranlov PJ "Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group." Gut 33 (1992): 252-5
2. Garau P, Orenstein SR, Neigut DA, Kocoshis SA "Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis." J Pediatr Gastroenterol Nutr 18 (1994): 481-5
3. Wright JP, O'Keefe EA, Cuming L, Jaskiewicz K "Olsalazine in maintenance of clinical remission in patients with ulcerative colitis." Dig Dis Sci 38 (1993): 1837-42
4. Jarnerot G "Clinical tolerance of olsalazine." Scand J Gastroenterol Suppl 148 (1988): 21-3
5. Loftus EV, Kane SV, Bjorkman D "Safety of 5-aminosalicylic acid agents in the treatment of ulcerative colitis: a systematic review." Am J Gastroenterol 98(9S) (2003): S249
6. Ewe K, Eckardt V, Kanzler G "Treatment of ulcerative colitis with olsalazine and sulphasalazine: efficacy and side-effects." Scand J Gastroenterol Suppl 148 (1988): 70-5
7. Feurle GE, Theuer D, Velasco S, Barry BA, Wordehoff D, Sommer A, Jantschek G, Kruis W "Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial." Gut 30 (1989): 1354-61
8. Wadworth AN, Fitton A "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease." Drugs 41 (1991): 647-64
9. "Product Information. Dipentum (olsalazine)." Pharmacia and Upjohn, Kalamazoo, MI.
10. Eland IA, van Puijenbroek EP, Sturkenboom MJ, Wilson JH, Stricker BH "Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands." Am J Gastroenterol 94 (1999): 2417-22
11. Meyers S, Sachar DB, Present DH, Janowitz HD "Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial." Gastroenterology 93 (1987): 1255-62
12. Ireland A, Mason CH, Jewell DP "Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis." Gut 29 (1988): 835-7
13. Mulder H, Gratama S "Azodisalicylate (Dipentum)-induced hepatitis?" J Clin Gastroenterol 11 (1989): 708-11
14. Wilcox GM, Reynolds JR, Galvanek EG "Nephrotoxicity associated with olsalazine." Am J Med 100 (1996): 238-40
15. Doman DB, Baum MD "Olsalazine sodium can cause myopia that can be clinically confused with the uveitis of inflammatory bowel disease." Am J Gastroenterol 87 (1992): 1684-5
Not all side effects for Dipentum may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
More about Dipentum (olsalazine)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.